Microbot Medical Appoints David J. Wilson to Board Committees

Microbot Medical Inc. (NASDAQ: MBOT) recently disclosed in an 8-K filing with the Securities and Exchange Commission that David J. Wilson has been appointed to serve on the company’s Audit Committee and Compensation Committee. Wilson was elected as a Class III director at the Annual Meeting of Stockholders held on December 17, 2024.

Bringing a wealth of experience to the role, Wilson has served as the Chief Executive Officer and a director of InnovHeart Corporation since March 2022. Prior to that, he held leadership positions at Haemonetics Corporation and various Johnson and Johnson (J&J) companies, including Cordis and Mentor. Wilson holds multiple medical device patents and has an extensive background in healthcare and medical device executive positions.

Microbot Medical highlights that Wilson’s appointment brings a valuable perspective to the board due to his experience in general management, research and development, marketing, sales, and supply chain management. The company also noted that Wilson is independent under NASDAQ rules, with no pre-existing arrangement regarding his election as a director.

As part of his appointment, Wilson will receive compensation in line with the company’s standard director compensation package. Microbot Medical has also entered into a standard director indemnification agreement with Wilson, aligning with Delaware General Corporation Law. The agreement provides indemnity to Wilson for actions taken in good faith and in the best interests of the company.

Furthermore, Microbot Medical disclosed the result of the recent Annual Meeting of Stockholders held on December 17, 2024. The meeting included voting on various proposals, including the election of directors and the approval of amendments to the company’s 2020 Omnibus Performance Award Plan.

In summary, Microbot Medical welcomes David J. Wilson to its board committees, recognizing his extensive industry experience and contributions towards the company’s strategic direction and governance.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Microbot Medical’s 8K filing here.

About Microbot Medical

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.